[go: up one dir, main page]

NI201900103A - Anticuerpos anti-ilt4 y fragmentos de unión a antígeno - Google Patents

Anticuerpos anti-ilt4 y fragmentos de unión a antígeno

Info

Publication number
NI201900103A
NI201900103A NI201900103A NI201900103A NI201900103A NI 201900103 A NI201900103 A NI 201900103A NI 201900103 A NI201900103 A NI 201900103A NI 201900103 A NI201900103 A NI 201900103A NI 201900103 A NI201900103 A NI 201900103A
Authority
NI
Nicaragua
Prior art keywords
binding fragments
antigen binding
antibodies
ilt4 antibodies
ilt4
Prior art date
Application number
NI201900103A
Other languages
English (en)
Inventor
A Zuniga Luis
Joyce-Shaikh Barbara
Blanusa Milan
Claudia Schuster Andrea
Schultze Kornelia
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NI201900103A publication Critical patent/NI201900103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen a ILT4 (transcrito de tipo inmunoglobulina 4) y combinaciones de los mismos, por ejemplo, con un anticuerpo anti-PD1. También se proporcionan procedimientos de uso de los mismos, por ejemplo, para tratar o prevenir el cáncer en un sujeto; y procedimientos de preparación de dichos anticuerpos y fragmentos.
NI201900103A 2017-04-07 2019-10-04 Anticuerpos anti-ilt4 y fragmentos de unión a antígeno NI201900103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483019P 2017-04-07 2017-04-07

Publications (1)

Publication Number Publication Date
NI201900103A true NI201900103A (es) 2019-10-31

Family

ID=62063229

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900103A NI201900103A (es) 2017-04-07 2019-10-04 Anticuerpos anti-ilt4 y fragmentos de unión a antígeno

Country Status (27)

Country Link
US (4) US11053315B2 (es)
EP (1) EP3606958A1 (es)
JP (2) JP7045392B2 (es)
KR (1) KR102357823B1 (es)
CN (1) CN110719917A (es)
AR (1) AR111362A1 (es)
AU (3) AU2018248294B2 (es)
BR (1) BR112019021000A2 (es)
CA (1) CA3057378A1 (es)
CL (1) CL2019002855A1 (es)
CO (1) CO2019011155A2 (es)
CR (1) CR20190459A (es)
DO (1) DOP2019000253A (es)
EA (1) EA201992402A1 (es)
EC (1) ECSP19072235A (es)
GE (1) GEP20227440B (es)
IL (1) IL269593A (es)
JO (1) JOP20190236B1 (es)
MX (1) MX392369B (es)
NI (1) NI201900103A (es)
PE (1) PE20191813A1 (es)
PH (1) PH12019502275A1 (es)
SG (1) SG11201909081YA (es)
TN (1) TN2019000272A1 (es)
TW (1) TWI796329B (es)
UA (1) UA126865C2 (es)
WO (1) WO2018187518A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN111699196A (zh) 2017-12-22 2020-09-22 震动疗法公司 针对lilrb2的抗体
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
US20210301020A1 (en) * 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
US12157768B2 (en) 2018-09-17 2024-12-03 Icahn School Of Medicine At Mount Sinai Anti-LILRB2 antibodies and methods of use thereof
AU2020229349A1 (en) * 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
CA3150428A1 (en) * 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
CN112442527B (zh) * 2019-08-27 2022-11-11 深圳市英马诺生物科技有限公司 孤独症诊断试剂盒、基因芯片、基因靶点筛选方法及应用
JP2023510132A (ja) * 2019-12-20 2023-03-13 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｄ－１アンタゴニスト、ｉｌｔ４アンタゴニストおよび化学療法剤の組合せを使用して癌を治療する方法
KR20220137007A (ko) * 2020-01-02 2022-10-11 머크 샤프 앤드 돔 엘엘씨 Pd-1 길항제, ilt4 길항제 및 렌바티닙 또는 그의 염을 사용하는 조합 암 치료
WO2021158413A1 (en) * 2020-02-05 2021-08-12 The Board Of Regents Of The University Of Texas System Novel lilrb2 antibodies and uses thereof
BR112022021684A2 (pt) 2020-05-01 2023-01-17 Ngm Biopharmaceuticals Inc Agente de ligação, anticorpo que liga especificamente ilt2 e ilt4 humanos, agente de ligação ou anticorpo, anticorpo, composição farmacêutica, polinucleotídeo isolado ou polinucleotídeos, vetor ou vetores, célula isolada, método para interromper, inibir ou bloquear a ligação de ilt2 e/ou ilt4, método para interromper, inibir ou bloquear a supressão induzida por ilt2 e/ou ilt4, método para inibir ou diminuir a atividade de células supressoras, método para intensificar ou aumentar a atividade de célula, método para intensificar ou aumentar a atividade de linfócito t citolítico (ctl), método para interromper, inibir ou bloquear a atividade de ilt2 e/ou ilt4, método para interromper, inibir ou bloquear ilt2 ou supressão induzida por ilt4, método para inibir ou diminuir a atividade de mdsc, método para intensificar ou aumentar a atividade de ctl, método para tratar câncer em um sujeito, método para inibir o crescimento tumoral em um sujeito, método para aumentar ou intensificar uma resposta imune, método para inibir o relapso de tumor ou reaparecimento de tumor em um sujeito, método para induzir uma imunidade persistente ou a longo prazo, método para ativar células mieloides, uso do agente de ligação ou anticorpo, composição farmacêutica e combinação
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도
CA3192390A1 (en) * 2020-09-17 2022-03-24 Merck Sharp & Dohme Llc Dosing regimens of anti-ilt4 antibody or its combination with anti-pd-1 antibody for treating cancer
AU2021365142A1 (en) * 2020-10-21 2023-06-08 Immune-Onc Therapeutics, Inc. Novel anti-lilrb2 antibodies and derivative products
WO2022217019A1 (en) * 2021-04-09 2022-10-13 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
JP2024529079A (ja) 2021-08-05 2024-08-01 イムノス セラピューティクス アーゲー 発現量が増加した改変型ｈｌａ－ｂ５７
AU2022322029A1 (en) 2021-08-05 2024-02-15 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023114346A2 (en) * 2021-12-16 2023-06-22 Merck Sharp & Dohme Llc Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
EP4499144A2 (en) * 2022-03-28 2025-02-05 Coherus Biosciences, Inc. Anti-ilt4 compositions and methods
EP4514856A2 (en) * 2022-04-29 2025-03-05 Merck Sharp & Dohme LLC Pharmaceutical formulations of an anti-ilt4 antibody or antigen-binding fragment thererof and methods of use
US20250269020A1 (en) * 2022-04-29 2025-08-28 Merck Sharp & Dohme Llc Stable formulations of anti-ilt4 antibodies or antigen-binding fragments thererof in combination with anti-pd-1 antibodies and methods of use thereof
CN114805580B (zh) * 2022-06-28 2022-09-06 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
TW202409088A (zh) * 2022-07-08 2024-03-01 中國商科望（蘇州）生物醫藥科技有限公司 抗lilrb2抗體及其用途
CN119604531A (zh) * 2022-07-29 2025-03-11 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
CN119768432A (zh) * 2022-08-22 2025-04-04 德琪(杭州)生物有限公司 新颖的抗lilrb2抗体和其用途
CN119698435A (zh) 2022-09-08 2025-03-25 江苏恒瑞医药股份有限公司 抗ilt4抗体及其医药用途
WO2024120526A1 (zh) * 2022-12-09 2024-06-13 诺纳生物（苏州）有限公司 抗ilt4抗体及其制备方法和应用
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
EP4637924A2 (en) * 2022-12-23 2025-10-29 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024165671A1 (en) 2023-02-08 2024-08-15 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
CN117925759B (zh) * 2024-01-23 2024-07-02 通化康元生物科技有限公司 林蛙多肽制剂及其在食品和化妆品中的应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
BR9917026B1 (pt) 1998-12-09 2010-10-19 método para fabricar glicoproteìnas tendo glicosilação do tipo humano.
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2003000199A2 (en) 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
AU2002360376B2 (en) 2001-11-14 2006-05-18 Immunex Corporation Modulation of LIR function to treat rheumatoid arthritis
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
ATE476993T1 (de) 2004-06-07 2010-08-15 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
DE102004034416A1 (de) 2004-07-15 2006-02-02 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Flüssige, strahlunghärtende Zusammensetzungen
EP1851251A2 (en) 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
WO2012012716A2 (en) 2010-07-23 2012-01-26 Regulus Therapeutics, Inc. Targeting micrornas for the treatment of fibrosis
TW201247700A (en) 2011-05-05 2012-12-01 Baylor Res Inst Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
HUE047947T2 (hu) 2011-12-30 2020-05-28 Cellscript Llc In vitro szintetizált ssRNS elõállítása és alkalmazása emlõssejtekbe történõ bevezetésre biológiai vagy biokémiai hatás indukálására
WO2013181438A2 (en) 2012-05-30 2013-12-05 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating pro-inflammatory immune response
US9944685B2 (en) 2012-07-02 2018-04-17 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
WO2014103534A1 (ja) 2012-12-28 2014-07-03 国立大学法人大阪大学 コラーゲン結合性分子を付加した改変ラミニンおよびその利用
EP2970373A1 (en) * 2013-03-12 2016-01-20 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
EP3831398A1 (en) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
CA2948871A1 (en) * 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016044022A1 (en) 2014-09-16 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016127247A1 (en) 2015-02-11 2016-08-18 University Health Network Methods and compositions for modulating lilr proteins
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
CN109689062B (zh) 2016-07-11 2023-02-17 丹娜法伯癌症研究院 使用抗PI3Kβ和抗免疫检查点药剂的组合治疗PTEN缺陷型上皮癌的方法
EP3491017A4 (en) 2016-07-29 2020-04-08 The Board of Regents of The University of Texas System METHODS OF IDENTIFYING ANTIBODIES BLOCKING LILRB RECEPTORS
CA3000514A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
JP2019524162A (ja) 2016-08-18 2019-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア モジュラーＡＡＶ送達システムによるＣＲＩＳＰＲ−Ｃａｓゲノム編集
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
EP3519564B1 (en) 2016-09-28 2023-11-15 Gavish-Galilee Bio Applications Ltd A universal platform for car therapy targeting a novel antigenic signature of cancer
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN111699196A (zh) 2017-12-22 2020-09-22 震动疗法公司 针对lilrb2的抗体
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体

Also Published As

Publication number Publication date
JOP20190236A1 (ar) 2019-10-06
DOP2019000253A (es) 2019-12-15
IL269593A (en) 2019-11-28
PH12019502275A1 (en) 2020-09-21
UA126865C2 (uk) 2023-02-15
JP2022084773A (ja) 2022-06-07
MX2019011927A (es) 2020-02-10
EP3606958A1 (en) 2020-02-12
KR102357823B1 (ko) 2022-01-28
GEP20227440B (en) 2022-11-25
CO2019011155A2 (es) 2019-10-21
JOP20190236B1 (ar) 2023-09-17
MX392369B (es) 2025-03-24
KR20190136064A (ko) 2019-12-09
US11053315B2 (en) 2021-07-06
CR20190459A (es) 2020-02-14
AU2024278314A1 (en) 2025-01-09
AU2021225143A1 (en) 2021-09-30
CN110719917A (zh) 2020-01-21
US20240228614A1 (en) 2024-07-11
JP7394160B2 (ja) 2023-12-07
EA201992402A1 (ru) 2020-02-19
SG11201909081YA (en) 2019-10-30
AU2018248294B2 (en) 2021-08-05
US20180298096A1 (en) 2018-10-18
WO2018187518A1 (en) 2018-10-11
US11897957B2 (en) 2024-02-13
ECSP19072235A (es) 2019-12-27
CL2019002855A1 (es) 2020-02-21
TW201839014A (zh) 2018-11-01
US12344670B2 (en) 2025-07-01
TN2019000272A1 (en) 2021-01-07
JP2020519235A (ja) 2020-07-02
US20220033496A1 (en) 2022-02-03
JP7045392B2 (ja) 2022-03-31
BR112019021000A2 (pt) 2020-05-05
CA3057378A1 (en) 2018-10-11
PE20191813A1 (es) 2019-12-26
AR111362A1 (es) 2019-07-03
US20220002403A1 (en) 2022-01-06
TWI796329B (zh) 2023-03-21
AU2018248294A1 (en) 2019-10-10
US11897956B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
NI201900103A (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
CL2023001092A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
CL2018000378A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
MX2020000960A (es) Anticuerpos anti-tigit.
MX2017001597A (es) Anticuerpos anti-pd-l1.
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112017020054A2 (pt) anticorpos para icos
CR20170200A (es) Conjugados de anticuerpo-farmaco
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
UY37915A (es) Anticuerpos específicos para cd47 y pd-l1